Physician profile
Jacob Hamad
NPI 1528557014
$2,126.94
in general payments reported to CMS, 2019-2025
22 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $141 · 2021: $147 · 2022: $181 · 2023: $338 · 2024: $340 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $317.52 | 2019-2022 | |
| Abbvie INC. | $292.81 | 2024-2025 | |
| Stryker Corporation | $264.98 | 2020-2025 | Valor, Ortholoc 3di Crosscheck, Augment Injectable |
| Integra Lifesciences Corporation | $188.11 | 2023-2025 | Tenoglide, Integra, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $160.59 | 2019-2025 | Stravix, Grafix Pl, Stravix Pl |
| Pinnacle, INC | $146.73 | 2019-2020 | |
| Sanara Medtech INC. | $120.74 | 2023 | Celleraterx |
| Amgen INC. | $119.70 | 2025 | Krystexxa |
| Organogenesis INC. | $118.30 | 2021-2025 | Apligraf, Puraply Wound Matrix |
| Depuy Synthes Sales INC. | $62.33 | 2020-2025 | Na, Va-Lcp |
| Kerecis Limited | $47.52 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Acumed LLC | $42.10 | 2024 | Osteomed |
| Mimedx Group, INC. | $38.01 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.86 | 2022 | |
| Janssen Pharmaceuticals, INC | $34.78 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $34.03 | 2024-2025 | Activ.A.C. |
| Next Science LLC | $30.34 | 2023 | Xperience, Blastx, Surgx |
| Nestle Healthcare Nutrition INC. | $15.67 | 2021 | |
| Hartmann USA, INC. | $15.15 | 2024 | Zetuvit Plus 10x10 P10 |
| Paratek Pharmaceuticals, INC. | $14.41 | 2024 | Nuzyra |
| Paragon 28, INC. | $13.76 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Hamad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.